Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice a fuzzy, unfocused feeling in the first weeks on Wegovy — harder to concentrate, slower to recall words, a general mental haziness that sits alongside the physical side effects. This is sometimes called brain fog, and it is a recognised pattern with semaglutide rather than something you imagined. For most people it eases considerably as the body adjusts to treatment, though it helps to understand what is likely driving it. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The phrase 'brain fog' covers a range of things, slow thinking, difficulty stringing sentences together, forgetting words mid-conversation, a general sense that your mind is working through thick glass. On Wegovy, these reports cluster in the early weeks of treatment, often starting around the same time as nausea and appetite suppression. That timing is not a coincidence, and tracing the symptom back to its most likely source is the first practical step.
The NHS medicines page for semaglutide lists the common side effects as primarily gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion. Cognitive symptoms are not enumerated separately, which can make people feel their experience is unusual. It is not. What is happening in many cases is that the body's resources are being redirected (managing GI discomfort, running on less food than usual, adjusting sleep patterns) and the brain is among the first places to feel the strain. If you are also not drinking enough because everything feels nauseating, mild dehydration compounds the effect quickly. Mental fatigue is the downstream result of several things happening at once, not necessarily a direct drug action on cognition.
It helps to keep a rough note of when the fog is worst: immediately after the injection, around mealtimes, or throughout the day. That pattern tells you and your prescriber something useful about what is driving it.
Before assuming Wegovy is doing something unusual to your brain, it is worth addressing the causes that respond to practical changes. Caloric reduction is the big one. Wegovy significantly reduces appetite, and some people eat far less than their body actually needs, particularly in protein. The brain is energetically expensive; an inadequate intake of protein and total calories over several weeks can dull mental performance noticeably. Prioritising protein at each meal, even when appetite is low, is standard clinical advice during GLP-1 treatment.
Hydration deserves equal attention. GI side effects (even mild ones) increase fluid losses, and many people unconsciously drink less because eating and drinking feel uncomfortable. Cognitive slowing is one of the earliest signs of underhydration, and it is reversible within hours of rehydrating properly. Aiming for water steadily through the day, rather than large amounts at once, tends to be more tolerable during the adjustment phase.
Sleep disruption is a third contributor. Nausea at night, changes in digestion, and the general upheaval of adjusting to a new medicine can fragment sleep, and the effects on next-day cognition are well established. None of these factors require stopping treatment. They require a little practical attention alongside it, and discussing them openly with your prescriber or aftercare team means they can be addressed properly.
Beyond the indirect causes, there is genuine scientific interest in how semaglutide acts on the brain directly. GLP-1 receptors exist throughout the central nervous system, including in regions involved in appetite regulation, reward and cognition. Semaglutide does cross into brain tissue, and researchers are actively investigating what this means for cognition, mood and neurological outcomes, as our overview of semaglutide and the brain explores in more detail. Our explainer on semaglutide and the blood-brain barrier covers the current evidence in detail.
What we can say with confidence is that the large clinical trials for Wegovy (including STEP 1, published in the New England Journal of Medicine) did not flag cognitive impairment as a significant finding in the semaglutide group. That does not mean individual experiences of brain fog are imaginary; it means the picture is more nuanced. Emerging research suggests semaglutide may have neuroprotective properties in some populations, and studies into its effects on conditions like Alzheimer's disease are ongoing, a topic we examine further in our guide to Wegovy's effects on the brain. The detail on how semaglutide affects the brain summarises what the evidence currently shows.
For now, the clinical consensus is that transient cognitive symptoms in early treatment are most often explained by the indirect causes above, not by lasting neurological change. That said, if your prescriber knows about it, they can help you distinguish the two.
Most reports of brain fog on Wegovy resolve within four to eight weeks without any dose change. The adjustment period for GI side effects and the adjustment period for cognitive ones tend to overlap, and as one settles so does the other. Consistency helps: injecting on the same day each week, keeping meals regular even if small, and giving the body time to calibrate.
There are situations that warrant a proper prescriber conversation rather than patient waiting. Brain fog that is worsening rather than improving, that appears after a dose increase and does not settle within two to three weeks, or that is severe enough to affect work or daily functioning should be reported promptly. Your prescriber can consider whether the titration pace needs adjusting, whether a different approach to managing GI side effects might help, or whether something else needs to be ruled out. This is not a case for adjusting your own dose or stopping treatment abruptly.
For context on the wider cost of accessing treatment and what clinical support actually looks like in practice, the guide to Wegovy costs in the UK covers what a legitimate private prescription should include beyond the medicine itself. If you are thinking about starting treatment or have questions about how your current experience compares to what is expected, the full Wegovy treatment page sets out the full picture. When you are ready, our prescribers review consultations the same day (a real clinician reads your answers, not software) and starting that conversation costs nothing.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.